Diabetes Core Update

Diabetes Core Update is a monthly podcast that presents and discusses the latest clinically relevant articles from the American Diabetes Association’s four science and medical journals – Diabetes, Diabetes Care, Clinical Diabetes, and Diabetes Spectrum. Each episode is approximately 15 minutes long and presents 5-6 recently published articles from ADA journals. Intended for practicing physicians and health care professionals, Diabetes Core Update discusses how the latest research and information published in journals of the American Diabetes Association are relevant to clinical practice and can be applied in a treatment setting. For more information about each of ADA’s science and medical journals, please visit www.diabetesjournals.org . Presented by: Neil Skolnik, M.D. , Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John J. Russell, M.D...

http://diabetescoreupdate.libsyn.com

subscribe
share





Diabetes Core Update SGLT2s and Diabetic Kidney Disease


In this special episode on SGLT-2 inhibitors and CKD Drs. John Russell and Neil Skolnik discuss the effects of the SGLT-2 inhibitors in decreasing progression of chronic kidney disease.    This special episide is supported by independent educational grant from AstraZeneca.

For more information about each of ADA’s science and medical journals, please visit www.diabetesjournals.org.

  1. Background, Epidemiology, and Pathophysiology of Diabetic Kidney Disease
  2. ADA Recommendations for Screening and Diagnosis of Diabetic Kidney Disease
  • ADA Recommendations for Treatment of CKD in Persons with Diabetes
  1. Review of the Literature
    1. SGLT-2 inhibitor effects on CV and Kidney Outcomes in Patients with T2DM
    2. Dapagliflozin in Patients with Chronic Kidney Disease
    3. CKD Testing in Patients with T2DM
    4. Second-Line Therapy for T2DM Management: The Treatment/Benefit Paradox of CV and Kidney Comorbidities
    5. eGFR dip After Starting SGLT-2 inhibitors
    6. Dapagliflozin in patients with T2DM and Stages 3b–4 chronic kidney disease

Presented by:

Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health

John J. Russell, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Director, Family Medicine Residency Program, Chair-Department of Family Medicine, Abington Jefferson Health


share







 2021-09-27  36m